<SEC-DOCUMENT>0001445305-12-002716.txt : 20120824
<SEC-HEADER>0001445305-12-002716.hdr.sgml : 20120824
<ACCEPTANCE-DATETIME>20120824161221
ACCESSION NUMBER:		0001445305-12-002716
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20120824
DATE AS OF CHANGE:		20120824

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeoStem, Inc.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-173855
		FILM NUMBER:		121054790

	BUSINESS ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170
		BUSINESS PHONE:		212-584-4171

	MAIL ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNICHE GROUP INC /DE
		DATE OF NAME CHANGE:	19951117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FIDELITY MEDICAL INC
		DATE OF NAME CHANGE:	19951025
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>a424b3stickersupplementaug.htm
<DESCRIPTION>424B3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 5f66f96 -->
		<!-- Copyright 2008-2012 WebFilings LLC. All Rights Reserved -->
		<title>424B3 Sticker Supplement (August 2012)</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s49b67894d5ae43a28cd668018415cb62"></a><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">This filing is made pursuant to Rule 424(b)(3)</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">under the Securities Act of 1933, as amended, in connection</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">with Registration No. 333-173855</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROSPECTUS SUPPLEMENT DATED AUGUST 24, 2012</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(To the Prospectus Supplement Dated September 30, 2011 To The Prospectus Dated June 13, 2011)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Extension of 2011 Common Stock Purchase Agreement for</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeoStem, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus supplement amends the prospectus supplement dated September 30, 2011 to the prospectus dated June 13, 2011, relating to the offering of up to $20,600,000 of our common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), to Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;) under a Common Stock Purchase Agreement entered into on September 28, 2011 (the &#8220;Purchase Agreement&#8221;).  You should read this prospectus supplement in conjunction with the prospectus supplement dated September 30, 2011 to the prospectus dated June 13, 2011, and this supplement is qualified by reference thereto, except to the extent that the information in this supplement supersedes the information contained in such prospectus supplement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Purchase Agreement had initially provided for a term through September 30, 2013.  On August 23, 2012 we and Aspire Capital agreed to extend the term of the Purchase Agreement for two additional years (that is, through September 30, 2015).  To date, we have not sold any shares of our Common Stock to Aspire Capital pursuant to the September 30, 2011 prospectus supplement, except that the 990,099 shares of our Common Stock representing the Commitment Shares have been issued to Aspire Capital pursuant to such prospectus supplement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No attempt has been made in this prospectus supplement to modify or update the other information presented in the September 30, 2011 prospectus supplement. This amendment does not reflect events occurring after the filing of the September 30, 2011 prospectus supplement or modify or update those disclosures affected by subsequent events. Accordingly, this amendment should be read in conjunction with the prospectus supplement dated September 30, 2011 and our other filings made with the Securities and Exchange Commission.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing in our Common Stock involves risks.  See &#8220;Risk Factors&#8221; beginning on page S-10 of the prospectus supplement dated September 30, 2011 to the prospectus dated June 13, 2011, as updated by the Risk Factors described in our periodic filings with the Securities and Exchange Commission incorporated by reference into the prospectus, including the risk factors set forth under the caption &#8220;Risk Factors&#8221; beginning on page 38 of our Annual Report on Form 10-K for the year ended December 31, 2011, and &#8220;Risk Factors&#8221; and &#8220;Risks Associated With the Erye Sale and the Equity Purchase Agreement&#8221; beginning on page 37 of our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2012.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;__________________________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the referenced prospectus supplement or prospectus are truthful or complete. Any representation to the contrary is a criminal offense.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The date of this supplement (to the prospectus supplement dated September 30, 2011 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to the prospectus dated June 13, 2011) is August 24, 2012.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br>	</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
